| abstract |
The present invention relates to the diagnosis and treatment of cancerous diseases, and in particular to mediating cytotoxicity of primary and metastatic human tumor cells. The diagnosis and treatment of the above cancerous diseases originates from isolated monoclonal antibodies or their cancerous disease modifying antibodies (CDMAB), eg, hepatocytes, optionally combined with one or more chemotherapeutic agents. And as a means for initiating a cytotoxic response in a human tumor, such as any primary or metastatic tumor site. The present invention further relates to binding assays that utilize the CDMAB of the present invention. [Selection] Figure 4 |